GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

First Tracks Biotherapeutics TRAX · USD

US listing · 🇺🇸 United States

Compare

49.70

+3.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About First Tracks Biotherapeutics

Its shares trade under the ticker TRAX. It has been listed since 20 April 2026.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
20 Apr 2026
Head office
10770 WATERIDGE CIRCLE, SAN DIEGO, CA, 92121
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ANB033 targets IL-15 and IL-2 receptors for autoimmune disease treatment in the US market.
  • Rosnilimab selectively depletes pathogenic T cells in peripheral and inflamed tissues.
  • ANB101 specifically targets plasmacytoid dendritic cells for inflammatory disease therapy.

Weaknesses

  • First Tracks Biotherapeutics operates in the US clinical-stage biotechnology sector with limited market presence.
  • The company's product pipeline includes only three therapeutic candidates as of 2026.
  • San Diego headquarters may limit access to broader biotech talent pools compared to major hubs.

Opportunities

  • Expanding ANB033's application to additional autoimmune conditions in the US market.
  • Leveraging Rosnilimab's selective T cell depletion for new inflammatory disease indications.
  • Increasing ANB101's use in plasmacytoid dendritic cell-targeted therapies across the US.

Threats

  • Competition from established biotech firms in the US immunology therapeutic space.
  • Regulatory delays affecting clinical trials for ANB033, Rosnilimab, and ANB101.
  • Potential market saturation in the US autoimmune disease treatment sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.